A Randomised, Double-blind Controlled Phase 4 Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency

Trial Profile

A Randomised, Double-blind Controlled Phase 4 Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 May 2016

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Chronic heart failure; Iron deficiency anaemia
  • Focus Therapeutic Use
  • Acronyms CONFIRM-HF
  • Sponsors Vifor
  • Most Recent Events

    • 23 May 2016 Results published in Vifor Pharma media release.
    • 23 May 2016 According to Vifor Pharma media release, based upon the findings of this and other study (FAIR-HF), the 2016 European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure (the ESC Guidelines HF 2016) recommended Ferinject for the treatment of iron deficiency in patients with systolic heart failure.
    • 01 Sep 2014 Status changed from active, no longer recruiting to completed, according to a Vifor Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top